Results 161 to 170 of about 3,283 (198)

Real-World Outcomes of Faricimab for Polypoidal Choroidal Vasculopathy in a Multi-ethnic Cohort: A 12-Month Retrospective Study. [PDF]

Ophthalmol Ther
Fu DJ, Riotto E, Nicholson L, Fasolo S, Trivizki O, Spooner K, Sivaprasad S, Faes L.   +7 more
europepmc   +1 more source

Dynamics of Hyper-Reflective Foci and Hard Exudates in Diabetic Macular Edema Treated with Faricimab. [PDF]

J Clin Med
Widmann-Sedlnitzky P, Huber KL, Steiner I, Gumpinger M, Stino H, Schmoll T, Schmidt-Erfurth U, Sacu S, Pollreisz A.   +8 more
europepmc   +1 more source

Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report. [PDF]

Ophthalmol Ther
Heck K, Hatz K, Cattaneo M, Pfister I, Magnin S, Ruscitti L, Stasik I, Tillmann A, Shamshiev M, Fang J, Weinberger A, Zweifel SA, Garweg JG, Eandi CM, Grimaldi G, Munk MR, Somfai GM, Ambresin A, Feltgen N.   +18 more
europepmc   +1 more source

A Response to: Letter to the Editor Regarding "Aflibercept 8 mg Versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials". [PDF]

Ophthalmol Ther
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel N.   +8 more
europepmc   +1 more source

Real-World Functional and Anatomical Outcomes of Intravitreal Faricimab in Suboptimal Responders With Neovascular Age-Related Macular Degeneration: A 24-Month Clinical Audit. [PDF]

Cureus
Sukumaran D, Benjamin D, Abdul Karim MN, Amankwah R, Maharajan P, Mubashar M, Sarmad A, Sharma P, Dhar-Munshi S.   +8 more
europepmc   +1 more source

Real-world outcomes after switching to faricimab in previously treated neovascular age-related macular degeneration: longitudinal outcomes up to 24 months. [PDF]

Int J Retina Vitreous
Egger D, Amesbauer F, Mohamed H, Thiel KE, Angermann R, Waldstein SM.   +5 more
europepmc   +1 more source

Short-term outcomes of intravitreal faricimab on refractory neovascular age-related macular degeneration patients in China. [PDF]

Front Med (Lausanne)
Zhou F, Bai W, Zhao Y, Jiang Q, Wang C, Xu X, Yao J.   +6 more
europepmc   +1 more source

Early Intraretinal Fluid Reduction is Linked to Vision Gains in Patients with Diabetic Macular Edema. [PDF]

Ophthalmol Ther
Wang Y, Hibar DP, Sadda S, Lim JI, Chan CK, Tan GS, Talcott KE, Gibson K, Maunz A, Lu H, Albrecht T, Amador M, Litts KM.   +12 more
europepmc   +1 more source

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Lancet, The, 2022
Geeta Menon, Frank G Holz, András Seres
exaly   +2 more sources